Patents by Inventor Kiyoshi Takayama
Kiyoshi Takayama has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11649281Abstract: It is an object of the present invention to provide an antibody that binds to a human PGE2 receptor subtype EP4 and inhibits the function of EP4, or a functional fragment thereof. It is another object of the present invention to provide a medicament comprising the aforementioned antibody or a functional fragment thereof. Mice were immunized with the human PGE2 receptor subtype EP4, and a monoclonal antibody that suppresses the intracellular cAMP level increase induced by EP4 was screened. In addition, the CDR sequences of the obtained monoclonal antibody were determined.Type: GrantFiled: August 29, 2019Date of Patent: May 16, 2023Assignee: NB HEALTH LABORATORY CO., LTD.Inventors: Kiyoshi Takayama, Tomoko Shimizu, Yuji Urushibata, Yukihiko Sugimoto
-
Publication number: 20220347202Abstract: To provide a technique for selecting a target cell producing a target substance that specifically binds to a desired cell membrane protein more rapidly and efficiently. A substrate 1 having a plurality of microwells 2 is provided. A first cell 3 expressing a target cell membrane protein on its surface is allowed to adhere to each of the microwells 2. One or two second cells 5 as a candidate of a target cell are introduced into each microwell 2, and are allowed to coexist with the first cell 3 in the microwell 2, and target substance 6 secreted by the second cell 5 is brought into contact with the first cell 3. A microwell 2 including the first cell 3 to which the target substance 6 binds is identified. The second cell 5 as the target cell is recovered from the identified microwell 2. One example of the target substance 6 is an antibody. Visualization may be performed by adding a label substance 7.Type: ApplicationFiled: May 11, 2022Publication date: November 3, 2022Applicant: NB HEALTH LABORATORY CO., LTD.Inventors: Masami ASHIDA, Yuji URUSHIBATA, Kiyoshi TAKAYAMA
-
Patent number: 11357787Abstract: To provide a technique for selecting a target cell producing a target substance that specifically binds to a desired cell membrane protein more rapidly and efficiently. A substrate 1 having a plurality of microwells 2 is provided. A first cell 3 expressing a target cell membrane protein on its surface is allowed to adhere to each of the microwells 2. One or two second cells 5 as a candidate of a target cell are introduced into each microwell 2, and are allowed to coexist with the first cell 3 in the microwell 2, and target substance 6 secreted by the second cell 5 is brought into contact with the first cell 3. A microwell 2 including the first cell 3 to which the target substance 6 binds is identified. The second cell 5 as the target cell is recovered from the identified microwell 2. One example of the target substance 6 is an antibody. Visualization may be performed by adding a label substance 7.Type: GrantFiled: February 17, 2020Date of Patent: June 14, 2022Assignee: NB HEALTH LABORATORY CO., LTD.Inventors: Masami Ashida, Yuji Urushibata, Kiyoshi Takayama
-
Publication number: 20220040216Abstract: To provide a technique for selecting a target cell producing a target substance that specifically binds to a desired cell membrane protein more rapidly and efficiently. A substrate 1 having a plurality of microwells 2 is provided. A first cell 3 expressing a target cell membrane protein on its surface is allowed to adhere to each of the microwells 2. One or two second cells 5 as a candidate of a target cell are introduced into each microwell 2, and are allowed to coexist with the first cell 3 in the microwell 2, and target substance 6 secreted by the second cell 5 is brought into contact with the first cell 3. A microwell 2 including the first cell 3 to which the target substance 6 binds is identified. The second cell 5 as the target cell is recovered from the identified microwell 2. One example of the target substance 6 is an antibody. Visualization may be performed by adding a label substance 7.Type: ApplicationFiled: February 17, 2020Publication date: February 10, 2022Applicant: NB HEALTH LABORATORY CO., LTD.Inventors: Masami ASHIDA, Yuji URUSHIBATA, Kiyoshi TAKAYAMA
-
Publication number: 20190389949Abstract: It is an object of the present invention to provide an antibody that binds to a human PGE2 receptor subtype EP4 and inhibits the function of EP4, or a functional fragment thereof. It is another object of the present invention to provide a medicament comprising the aforementioned antibody or a functional fragment thereof. Mice were immunized with the human PGE2 receptor subtype EP4, and a monoclonal antibody that suppresses the intracellular cAMP level increase induced by EP4 was screened. In addition, the CDR sequences of the obtained monoclonal antibody were determined.Type: ApplicationFiled: August 29, 2019Publication date: December 26, 2019Applicant: NB Health Laboratory Co., Ltd.Inventors: Kiyoshi Takayama, Tomoko Shimizu, Yuji Urushibata, Yukihiko Sugimoto
-
Patent number: 10435465Abstract: It is an object of the present invention to provide an antibody that binds to a human PGE2 receptor subtype EP4 and inhibits the function of EP4, or a functional fragment thereof. It is another object of the present invention to provide a medicament comprising the aforementioned antibody or a functional fragment thereof. Mice were immunized with the human PGE2 receptor subtype EP4, and a monoclonal antibody that suppresses the intracellular cAMP level increase induced by EP4 was screened. In addition, the CDR sequences of the obtained monoclonal antibody were determined.Type: GrantFiled: September 24, 2015Date of Patent: October 8, 2019Assignee: NB HEALTH LABORATORY CO. LTD.Inventors: Kiyoshi Takayama, Tomoko Shimizu, Yuji Urushibata, Yukihiko Sugimoto
-
Patent number: 9505844Abstract: An anti-human-CC-motif-receptor-7 (anti-human-CCR7) antibody which is useful as a therapeutic agent for tissue fibrosis or cancer, and a pharmaceutical composition containing the anti-human CCR7 antibody, and the like is described. An anti-human CCR7 antibody specifically binding to an extracellular domain of human CCR7, having a heavy chain CDR3 containing an amino acid sequence represented by SEQ ID NO: 7, SEQ ID NO: 17, SEQ ID NO: 27, SEQ ID NO: 37, SEQ ID NO: 47, SEQ ID NO: 57, SEQ ID NO: 67, or SEQ ID NO: 77 is provided. Also provided is an anti-human CCR7 antibody having heavy chain CDRs 1-3 and light chain CDRs 1-3 containing amino acid sequences represented by SEQ ID NOs: 5-10, 15-20, 25-30, 35-40, 45-50, 55-60, 65-70, or 75-80. The anti-human CCR7 antibody of the present invention may be used as an active ingredient of a therapeutic agent for tissue fibrosis or cancer.Type: GrantFiled: September 18, 2014Date of Patent: November 29, 2016Assignees: SEKISUI CHEMICAL CO., LTD., NB HEALTH LABORATORY CO., LTD.Inventors: Naoki Nishiguchi, Akiyoshi Hirayama, Masahiro Furutani, Tatsuo Shimizu, Kiyoshi Takayama, Tomoko Shimizu, Kazuya Suzuki
-
Publication number: 20160075780Abstract: It is an object of the present invention to provide an antibody that binds to a human PGE2 receptor subtype EP4 and inhibits the function of EP4, or a functional fragment thereof. It is another object of the present invention to provide a medicament comprising the aforementioned antibody or a functional fragment thereof. Mice were immunized with the human PGE2 receptor subtype EP4, and a monoclonal antibody that suppresses the intracellular cAMP level increase induced by EP4 was screened. In addition, the CDR sequences of the obtained monoclonal antibody were determined.Type: ApplicationFiled: September 24, 2015Publication date: March 17, 2016Applicant: NB HEALTH LABORATORY CO., LTD.Inventors: Kiyoshi Takayama, Tomoko Shimizu, Yuji Urushibata, Yukihiko Sugimoto
-
Patent number: 9175080Abstract: It is an object of the present invention to provide an antibody that binds to a human PGE2 receptor subtype EP4 and inhibits the function of EP4, or a functional fragment thereof. It is another object of the present invention to provide a medicament comprising the aforementioned antibody or a functional fragment thereof. Mice were immunized with the human PGE2 receptor subtype EP4, and a monoclonal antibody that suppresses the intracellular cAMP level increase induced by EP4 was screened. In addition, the CDR sequences of the obtained monoclonal antibody were determined.Type: GrantFiled: September 28, 2011Date of Patent: November 3, 2015Assignee: NB HEALTH LABORATORY CO., LTD.Inventors: Kiyoshi Takayama, Tomoko Shimizu, Yuji Urushibata, Yukihiko Sugimoto
-
Patent number: 9018238Abstract: There is provided an inhibitor that inhibits casein kinase 1? and casein kinase 1?, and thus, there is also provided a pharmaceutical agent useful for the treatment and/or prevention of a disease, with the pathological condition of which the mechanism of activation of casein kinase 1? or casein kinase 1? is associated. Particularly, the above-described inhibitor is used to provide a pharmaceutical agent useful for the treatment of circadian rhythm disorder (including sleep disorder), central neurodegenerative disease, and cancer.Type: GrantFiled: December 28, 2009Date of Patent: April 28, 2015Assignees: Pharmadesign, Inc., NB Health Laboratory Co., Ltd.Inventors: Masako Okamoto, Kiyoshi Takayama
-
Publication number: 20150017167Abstract: An object of the present invention is to provide a novel anti-human CCR7 antibody useful as a therapeutic agent for tissue fibrosis or cancer, and a pharmaceutical composition containing the anti-human CCR7 antibody, and the like. An anti-human CCR7 antibody specifically binding to an extracellular domain of human CCR7, having a heavy chain CDR3 containing an amino acid sequence represented by SEQ ID NO: 7, SEQ ID NO: 17, SEQ ID NO: 27, SEQ ID NO: 37, SEQ ID NO: 47, SEQ ID NO: 57, SEQ ID NO: 67, or SEQ ID NO: 77 is provided. Also provided is an anti-human CCR7 antibody having heavy chain CDRs 1-3 and light chain CDRs 1-3 containing amino acid sequences represented by SEQ ID NOs: 5-10, 15-20, 25-30, 35-40, 45-50, 55-60, 65-70, or 75-80. Preferably, the antibody has an activity of interfering with a CCR7-dependent intracellular signal transduction mechanism caused by CCR7 ligand stimulation.Type: ApplicationFiled: September 18, 2014Publication date: January 15, 2015Inventors: Naoki NISHIGUCHI, Akiyoshi HIRAYAMA, Masahiro FURUTANI, Tatsuo SHIMIZU, Kiyoshi TAKAYAMA, Tomoko SHIMIZU, Kazuya SUZUKI
-
Publication number: 20150010998Abstract: An object of the present invention is to provide a novel anti-human CCR7 antibody useful as a therapeutic agent for tissue fibrosis or cancer, and a pharmaceutical composition containing the anti-human CCR7 antibody, and the like. An anti-human CCR7 antibody specifically binding to an extracellular domain of human CCR7, having a heavy chain CDR3 containing an amino acid sequence represented by SEQ ID NO: 7, SEQ ID NO: 17, SEQ ID NO: 27, SEQ ID NO: 37, SEQ ID NO: 47, SEQ ID NO: 57, SEQ ID NO: 67, or SEQ ID NO: 77 is provided. Also provided is an anti-human CCR7 antibody having heavy chain CDRs 1-3 and light chain CDRs 1-3 containing amino acid sequences represented by SEQ ID NOs: 5-10, 15-20, 25-30, 35-40, 45-50, 55-60, 65-70, or 75-80. Preferably, the antibody has an activity of interfering with a CCR7-dependent intracellular signal transduction mechanism caused by CCR7 ligand stimulation.Type: ApplicationFiled: September 18, 2014Publication date: January 8, 2015Inventors: Naoki NISHIGUCHI, Akiyoshi HIRAYAMA, Masahiro FURUTANI, Tatsuo SHIMIZU, Kiyoshi TAKAYAMA, Tomoko SHIMIZU, Kazuya SUZUKI
-
Patent number: 8865170Abstract: The present invention is novel anti-human-CC-motif-receptor-7 (anti-human-CCR7) antibodies useful for treating tissue fibrosis or cancer, and pharmaceutical compositions containing the anti-human-CCR7 antibodies. The invention includes an anti-human-CCR7 antibody specifically binding to an extracellular domain of human CCR7, having a heavy chain CDR3 containing an amino acid sequence represented by SEQ ID NO: 7, SEQ ID NO: 17, SEQ ID NO: 27, SEQ ID NO: 37, SEQ ID NO: 47, SEQ ID NO: 57, SEQ ID NO: 67, or SEQ ID NO: 77. The invention also includes an anti-human-CCR7 antibody having heavy chain CDRs 1-3 and light chain CDRs 1-3 containing amino acid sequences represented by SEQ ID NOs: 5-10, 15-20, 25-30, 35-40, 45-50, 55-60, 65-70, or 75-80. Preferably, the antibody has an activity of interfering with a CCR7-dependent intracellular signal transduction mechanism caused by CCR7 ligand stimulation.Type: GrantFiled: September 27, 2011Date of Patent: October 21, 2014Assignees: Sekisui Chemical Co., Ltd., NE Health Laboratory Co., Ltd.Inventors: Naoki Nishiguchi, Akiyoshi Hirayama, Masahiro Furutani, Tatsuo Shimizu, Kiyoshi Takayama, Tomoko Shimizu, Kazuya Suzuki
-
Patent number: 8710231Abstract: There is provided a novel oxazolone derivative having inhibitory activity against casein kinase 1? and casein kinase 1?. In addition, the present inhibitor inhibits casein kinase 1? and casein kinase 1?, and thus there is also provided a pharmaceutical agent useful for the treatment and/or prevention of diseases, with the pathological conditions of which the activation mechanism of casein kinase 1? or casein kinase 1? is associated. There is further provided a pharmaceutical agent useful for the treatment of, particularly, circadian rhythm disorder (including sleep disorder), central neurodegenerative disease, and cancer. An inhibitor of casein kinase 1? and casein kinase 1? comprising, as an active ingredient, an oxazolone derivative represented by the following general formula (1), a salt thereof, a solvate thereof, or a hydrate thereof: wherein X represents a halogen atom which is fluorine, chlorine, bromine or iodine.Type: GrantFiled: August 8, 2011Date of Patent: April 29, 2014Assignees: Pharmadesign, Inc., NB Health Laboratory Co., Ltd.Inventors: Masako Okamoto, Kiyoshi Takayama
-
Publication number: 20130195869Abstract: An object of the present invention is to provide a novel anti-human CCR7 antibody useful as a therapeutic agent for tissue fibrosis or cancer, and a pharmaceutical composition containing the anti-human CCR7 antibody, and the like. An anti-human CCR7 antibody specifically binding to an extracellular domain of human CCR7, having a heavy chain CDR3 containing an amino acid sequence represented by SEQ ID NO: 7, SEQ ID NO: 17, SEQ ID NO: 27, SEQ ID NO: 37, SEQ ID NO: 47, SEQ ID NO: 57, SEQ ID NO: 67, or SEQ ID NO: 77 is provided. Also provided is an anti-human CCR7 antibody having heavy chain CDRs 1-3 and light chain CDRs 1-3 containing amino acid sequences represented by SEQ ID NOs: 5-10, 15-20, 25-30, 35-40, 45-50, 55-60, 65-70, or 75-80. Preferably, the antibody has an activity of interfering with a CCR7-dependent intracellular signal transduction mechanism caused by CCR7 ligand stimulation.Type: ApplicationFiled: September 27, 2011Publication date: August 1, 2013Applicants: NB Health Laboratory Co., Ltd, Sekisui Chemical Co., Ltd.Inventors: Naoki Nishiguchi, Akiyoshi Hirayama, Masahiro Furutani, Tatsuo Shimizu, Kiyoshi Takayama, Tomoko Shimizu, Kazuya Suzuki
-
Publication number: 20130197199Abstract: It is an object of the present invention to provide an antibody that binds to a human PGE2 receptor subtype EP4 and inhibits the function of EP4, or a functional fragment thereof. It is another object of the present invention to provide a medicament comprising the aforementioned antibody or a functional fragment thereof. Mice were immunized with the human PGE2 receptor subtype EP4, and a monoclonal antibody that suppresses the intracellular cAMP level increase induced by EP4 was screened. In addition, the CDR sequences of the obtained monoclonal antibody were determined.Type: ApplicationFiled: September 28, 2011Publication date: August 1, 2013Applicants: NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITY, NB HEALTH LABORATORY CO., LTD.Inventors: Kiyoshi Takayama, Tomoko Shimizu, Yuji Urushibata, Yukihiko Sugimoto
-
Publication number: 20130137730Abstract: There is provided a novel oxazolone derivative having inhibitory activity against casein kinase 1? and casein kinase 1?. In addition, the present inhibitor inhibits casein kinase 1? and casein kinase 1?, and thus there is also provided a pharmaceutical agent useful for the treatment and/or prevention of diseases, with the pathological conditions of which the activation mechanism of casein kinase 1? or casein kinase 1? is associated. There is further provided a pharmaceutical agent useful for the treatment of particularly, circadian rhythm disorder (including sleep disorder), central neurodegenerative disease, and cancer. An inhibitor of casein kinase 1? and casein kinase 1? comprising, as an act ingredient, an oxazolone derivative represented by the following general formula (1), a salt thereof, a solvate thereof, or a hydrate thereof: wherein X represents a halogen atom (which may be any one of a fluorine atom, a chlorine atom, a bromine atom, and an iodine atom).Type: ApplicationFiled: August 8, 2011Publication date: May 30, 2013Applicants: NB HEALTH LABORATORY CO., LTD., PHARMADESIGN, INC.Inventors: Masako Okamoto, Kiyoshi Takayama
-
Publication number: 20120196282Abstract: A method of regenerating an elastic fiber according in the present invention is characterized in that the method comprises bringing an elastic fiber regenerating agent containing LTBP-4 into contact with a cell having the fiber regenerating ability. Preferably, the elastic fiber regenerating agent further contains DANCE and/or LTBP-4 expression potentiating factor. According to the present invention, the elastic fiber regenerating ability is further enhanced than so far.Type: ApplicationFiled: January 28, 2011Publication date: August 2, 2012Inventors: Tomoyuki NAKAMURA, Kyoko Takagi, Kiyoshi Takayama
-
Patent number: 8124744Abstract: Compounds represented by formula (I) and the formula (IV) have an inhibitory activity of MMP-9 production, therefore, are useful as a medicine agent with fewer side effects than conventional MMP enzyme activity inhibitors, as a prophylactic and therapeutic drug for oncogenic angiogenesis, chronic rheumatoid arthritis, vascular intimal thickening after a percutaneous coronary transluminal angioplasty, vascular atherosclerosis, hemorrhagic apoplexy, acute myocardial infarction, chronic heart failure, aneurysm, lung cancer metastasis, adult respiratory distress syndrome, asthma, interstitial pulmonary fibrosis, chronic rhinosinusitis, bronchitis or chronic obstructive pulmonary disease (COPD).Type: GrantFiled: May 1, 2007Date of Patent: February 28, 2012Assignee: Taisho Pharmaceutical Co., Ltd.Inventors: Masato Kashimura, Madoka Kawamura, Toshifumi Asaka, Kiyoshi Takayama, Haruhisa Ogita
-
Publication number: 20110294857Abstract: There is provided an inhibitor that inhibits casein kinase 1? and casein kinase 1?, and thus, there is also provided a pharmaceutical agent useful for the treatment and/or prevention of a disease, with the pathological condition of which the mechanism of activation of casein kinase 1? or casein kinase 1? is associated. Particularly, the above-described inhibitor is used to provide a pharmaceutical agent useful for the treatment of circadian rhythm disorder (including sleep disorder), central neurodegenerative disease, and cancer.Type: ApplicationFiled: December 28, 2009Publication date: December 1, 2011Applicants: NB HEALTH LABORATORY CO. LTD., PHARMADESIGN, INC.Inventors: Masako Okamoto, Kiyoshi Takayama